SCHEMBL965974

SCHEMBL965974

Cc1nn(C)c(-n2ccc3cc(Cl)ccc32)c1/C=C/C(=O)NS(=O)(=O)Cc1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
MAPT P10636 1/20 0.37
NR2F2 P24468 1/20 0.37
HTT P42858 1/20 0.37
HDAC1 Q13547 3/20 0.36
HDAC8 Q9BY41 3/20 0.36
HDAC3 O15379 2/20 0.36
HDAC4 P56524 2/20 0.36
HDAC7 Q8WUI4 2/20 0.36
HDAC2 Q92769 2/20 0.36
HDAC10 Q969S8 2/20 0.36
HDAC11 Q96DB2 2/20 0.36
HDAC6 Q9UBN7 2/20 0.36
HDAC9 Q9UKV0 2/20 0.36
HDAC5 Q9UQL6 2/20 0.36
PLA2G4A P47712 2/20 0.36
MCL1 Q07820 1/20 0.35
PHGDH O43175 5/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL965976 1.00 MEN1 (0.38) MEN1KMT2ASMN1; SMN2MAPTNR2F2
SCHEMBL965317 0.87 PTGER3 (0.40) SMN1; SMN2MAPTNR2F2HTTHDAC1
SCHEMBL965316 0.87 PTGER3 (0.40) SMN1; SMN2MAPTNR2F2HTTHDAC1
SCHEMBL5111983 0.86 SMN1; SMN2 (0.41) MEN1KMT2ASMN1; SMN2MAPTNR2F2
SCHEMBL5111968 0.86 SMN1; SMN2 (0.41) MEN1KMT2ASMN1; SMN2MAPTNR2F2
SCHEMBL27794000 0.85 MEN1 (0.40) MEN1KMT2ASMN1; SMN2MAPTNR2F2
SCHEMBL967355 0.85 PPARG (0.48) SMN1; SMN2MAPTNR2F2HTTPPARG
SCHEMBL967358 0.85 PPARG (0.48) SMN1; SMN2MAPTNR2F2HTTPPARG
SCHEMBL962525 0.85 MAPT (0.37) SMN1; SMN2MAPTNR2F2HTTPHGDH
SCHEMBL962524 0.85 MAPT (0.37) SMN1; SMN2MAPTNR2F2HTTPHGDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-01-13 US disclosed
EP-2118066-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA Takeda Pharmaceutical Company Limited (JP) 2009-11-18 EP disclosed
WO-2008099794-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-21 WO disclosed
US-20080194617-A1 Fused ring compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194617-A1 Fused ring compound SLC5A1, SLC5A2, GPR119 MEN1 1234/4885KMT2A 1809/4885SMN1; SMN2 3745/4885
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA PPARA, PPARD, PPARG MEN1 4766/4885KMT2A 2017/4885SMN1; SMN2 4710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.